Title: A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20150401
Title: Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20141001
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120801
Title: Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery.
Journal: Archives of pharmacal research 20120201
Title: Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.
Journal: British journal of cancer 20111108
Title: Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?
Journal: Journal of biomedicine & biotechnology 20110101
Title: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Journal: Cancer research 20100501
Title: Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Journal: Journal of medicinal chemistry 20100311
1015082-77-5 | Borate(1-), trifluoro[3-(hydroxymethyl)phenyl]-, potassium (1:1), (T-4)- | AA0004L9 | MFCD09993091